ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on December 18, 2020, covering events occurring on December 15, 2020, and December 18, 2020. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Ann Arbor, Michigan. Its common stock (NDRA) and warrants (NDRAW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing reports on a specific capital raising event rather than periodic financial performance. Key metrics include:
- Net Proceeds: Approximately $4.9 million received after deducting underwriting discounts, commissions, and offering expenses.
- Shares Issued: 7,143,000 shares of common stock in the base offering plus 714,286 shares from the full exercise of the over-allotment option, totaling 7,857,286 shares.
- Revenue, Profit, and Cash Flow: The filing text does not provide clear values for revenue, profit, operating cash flow, or margins as this is a transactional report.
- Debt and Liquidity: The filing text does not provide clear values for total debt or existing liquidity positions prior to this transaction.
Material Changes
The primary material change is the entry into a Material Definitive Agreement (Underwriting Agreement) with ThinkEquity, a division of Fordham Financial Management, Inc. This resulted in a significant increase in the Company's cash position through the issuance of new equity. The over-allotment option was exercised in full on December 16, 2020, and the offering closed on December 18, 2020.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard indemnification provisions in the Underwriting Agreement. The Company agreed to indemnify the Underwriter against certain liabilities under the Securities Act of 1933. The offering was conducted pursuant to an effective Form S-3 registration statement.
Investor Verification Checklist
- Verify the final closing price per share to calculate the total gross proceeds.
- Confirm the exact amount of underwriting discounts and commissions deducted to reach the $4.9 million net figure.
- Review the Company's most recent 10-K or 10-Q to assess the impact of these proceeds on total liquidity and runway.
- Check for any subsequent filings regarding the use of proceeds or changes in capital structure.